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Background: Aminoquinoline/steroid conjugates were synthesized based on the fact that steroid transporters have
been shown to accept and carry a variety of drugs. So, in continuing our research of antileishmanial and
antitubercular drugs, aminoquinoline/steroid conjugates (12, 13, and 14) were regioselectively synthesized via
1, 3-dipolar cycloaddition of alkynes 3, 5, and 7 with azide 12. The aminoquinoline/steroids conjugates were evaluated
in vitro against Leishmania major and Mycobacterium tuberculosis.
Results: Regioselective synthesis of the novel aminoquinoline/steroid conjugates was achieved in very high
yield. All aminoquinoline/steroid conjugates (12, 13, and 14) exhibited best results against Leishmania and M.
tuberculosis than the respective alkyne intermediate structures (3, 5, and 7, respectively). Among them, the
compound 12 exhibited the best activity for M. tuberculosis (MIC= 8.8 μM). This result is comparable to drugs
commonly used in tuberculosis treatment. Also, for antileishmanial assay, the aminoquinoline/steroid conjugates
demonstrated a significant activity against promastigote and amastigote forms of L. major.
Conclusions: Addition of a steroid group to aminoquinoline molecules enhanced the leishmanicidal and
antitubercular activities. These results highlight the importance of steroids as carrier.
Keywords: Antileishmanial drugs, Antituberculosis drugs, Click chemistry, Quinoline, SteroidBackground
Quinolines are among the most important antimalarial
drugs ever used [1,2]. In addition, quinoline derivatives
have also demonstrated a variety of biological properties
that includes antiviral, anti-inflammatory, antitubercular,
and antileishmanial activities [2-5]. Leishmaniasis is a dis-
ease caused by parasitic protozoans of the genus Leish-
mania. Over 20 different Leishmania species can infect
humans and cause a wide spectrum of symptoms. It has an
estimated prevalence of 12 million cases worldwide, which
is continuing to increase, with 1.5–2 million new cases
each year [6]. With no available vaccine, the chemotherapy
is a major control for the disease. However, the treatment
options are severely limited and first line treatment is based
on pentavalent antimonials that have been used in thera-
peutics for more than half a century [7]. Tuberculosis (TB)* Correspondence: david.silva@ufjf.edu.br
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in any medium, provided the original work is pis another important neglected disease. TB is more preva-
lent in the world today than at any other time in human
history. Mycobacterium tuberculosis (MTB), the pathogen
responsible for TB, uses diverse strategies to survive in a
variety of host lesions and to evade immune surveillance
[7,8]. The last 20 years have seen the worldwide appearance
of multidrug-resistant TB, followed by extensively drug-
resistant TB, and most recently, strains that are resistant to
all antituberculosis drugs [9]. Since the discovery of rifam-
picin (1960), no new drugs have been developed specifically
against mycobacteria [10]. Also, only within the last few
years some promising drug candidates have emerged [11].
Considering the inefficacy and the high toxicity of the cur-
rently used drugs for the treatment of these infectious dis-
eases, as well as the emergence of drug-resistant strains of
the causative organisms, the development of new leishma-
nicidal and antitubercular agents is extremely important.
Bioconjugation has emerged as a fast growing technol-
ogy and aims at the ligation of two or more molecules to
form new complexes with the combined properties of
their individual components [12]. To make this linkage,pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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units, since they are stable to metabolic degradation and
capable of hydrogen bonding, which can be favorable in
binding to biomolecular targets and also improves solu-
bility [13]. Although the 1,2,3-triazole structural moiety
does not occur in nature, the synthetic molecules con-
taining the 1,2,3-triazole unit show diverse biological ac-
tivities including antibacterial, herbicidal, fungicidal,
anti-allergic, and anti-HIV [14]. Aminoquinoline/cholic
acid conjugates were synthesized based on the fact that
steroid transporters have been shown to accept and
carry a variety of drugs [15]. Cholic acid is the most
common form of the steroid and its derivatives are
known to exhibit antimicrobial activities [16]. Bile acids
are amphiphilic molecules which may represent alterna-
tives for chemotherapeutic agents by acting synergistically
with antibiotics as membrane permeabilizers [17-21].
Moreover, several bile acid/drug conjugates are shown to
possess better activity than the precursor [22,23].
In a previous study, we demonstrate that 4-amino-
7-chloroquinoline derivatives showed an interesting
antileishmanial and anti-MTB activities [24]. In con-
tinuation of this study were synthesized aminoquino-
line conjugate with steroids in the expectation of
improving its biological activity.
Methods
General experimental techniques and apparatus
TLC was performed on precoated silica gel F254 plates
(0.25 mm; E. Merck). Infrared spectra were recorded on
Schimadzu 8400 series FTIR instrument. 1 H NMR spec-
tra were recorded on a Bruker AC-300 and 500 spectro-
meters at 300.13 and 500.13 MHz and 13C NMR spectra
were recorded on a Bruker AC-300 at 75 MHz. The
chemical shifts are given in parts per million relative to
tetramethylsilane. Mass spectra were recorded on LC–
MS/MS-TOF API QSTAR PULSAR spectrometer, and
samples were introduced by infusion method using Elec-
tro spray Ionization Technique. Standard work up: after
extraction of all the reactions, the organic extracts were
washed with water and brine and dried over anhydrous
Na2SO4 and concentrated in vacuum.
Synthesis of terminal acetylenes
General synthetic procedure for N-(7-chloroquinolin-4-yl)
alkyl-diamine) (2, 4, and 6)
A mixture of 4,7-dichloroquinoline (2.0 g, 10.1 mmol)
and the corresponding diamines (50.0 mmol), ethane-
1,2-diamine, propane-1,3-diamine, or buthane-1,4-di-
amine, was heated at 80°C for 1 h without stirring for
1 h and then at 110°C for 4–6 h with continued stirring
to drive the reaction to completion. The reaction mix-
ture was cooled to room temperature and diluted with
dichloromethane. The organic layer was successivelywashed with 5% NaOH (30 mL) followed by water wash
and then finally with brine. The organic layer was dried
over anhydrous Na2SO4 and solvent was removed under
reduced pressure to afford the compounds 2, 4, and 6,
at 80–90% yield.
N-(7-chloroquinolin-4-yl)ethane-1,2-diamine (2) [25]:
Yellow solid, yield: 90%; mp = 141°C (145-147°C).
N-(7-chloroquinolin-4-yl)propane-1,3-diamine (4) [25]:
Yellow solid, yield: 90%; mp = 97°C (96–98°C) [25].
N-(7-chloroquinolin-4-yl)buthane-1,4-diamine (6) [25]:
Yellow solid, yield: 80%; mp = 123°C (122–124°C).
General synthetic procedure for 7-chloro-N-(3-(prop-2-
ynylamino)alquil)quinolin-4-amine (3, 5, and 7)
The compounds 2, 4, and 6 (6.8 mmol) and propar-
gyl bromide (13.6 mmol), in presence of K2CO3
(13.6 mmol), were dissolved in EtOH (5.0 mL). The
reaction mixture was stirred at 0°C for 2 h and then
at 25°C for 48 h. Solvent was removed in vacuum
until dry. The crude reaction product was purified by
flash chromatography (eluent: MeOH/CH2Cl2 5:95)
producing the compounds 3, 5, and 7, respectively
(2.5 mmol) in 60% yield as yellow solid.
7-chloro-N-(2-(prop-2-ynylamino)ethyl)quinolin-4-
amine (3) [24]: Yield: 60%, mp= 99°C.
7-chloro-N-(3-(prop-2-ynylamino)propyl)quinolin-4-
amine (5) [24]: Yield: 60%, mp= 75°C.
7-chloro-N-(4-(prop-2-ynylamino)butyl)quinolin-4-
amine (7) [24]: Yield: 62%, mp= 72°C.
Synthesis of terminal azide
Synthesis of methyl 3α,7α,12α-trihydroxy-5β-cholane-24-
oate (9)
Compound 9 was synthesized in overall good yield start-
ing from bile acid 8 using the literature procedure [24].
White solid, m.p. 158°C.
Methyl-3α-mesyloxy-7α-12α-dihydroxy-5β-cholane-24-
oate (10) [23]: To a solution of 9 (2.0 g, 4.92 mmol) in
CH2Cl2 (20 mL) was added triethylamine (6.4 mL,
49.2 mmol) at 0°C. Methane sulfonyl chloride (0.5 mL,
4.92 mmol) was added dropwise for 10 min at 0°C. The
reaction mixture was extracted with CH2Cl2/H2O. Or-
ganic layer was washed with NaHCO3, water, and brine.
The solvent was evaporated under reduced pressure.
The crude product was purified by column chromatog-
raphy (AcOEt/Hex 2:8) to obtain pure product 7 (1.9 g).
Synthesis of methyl-3β-azido-7α,12α-dihydroxy-5β-cholane-
24-oate (11)
The compound 10 was reacted with NaN3 (5 equiv) in
DMF for 24 h at 120°C to give product 11 [23]. White
solid, m.p. 175°C.
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The alkyne 3, 5, or 7 (1 equiv) and the azide 11 (1.3
equiv) were dissolved in DMSO/H2O 4:1 (5 mL). To this
solution, CuSO4.5H2O (0.05 equiv) and sodium ascor-
bate (0.40 equiv) were added. The reaction mixture was
stirred for 48 h at room temperature and it was then
extracted with CH2Cl2/H2O. Organic layer was washed
with NaHCO3, water, and brine. The solvent was
evaporated under reduced pressure and crude prod-
uct was purified by column chromatography on silica
gel using 30% MeOH/CH2Cl2 system to obtain ami-
noquinoline/bile acid conjugates 12, 13, or 14, re-




lane-24-oate (12): Yellow crystalline solid; m.p. 128°C,
υmax (KBr): 3340 (NH), 2930 (CH);
1H NMR (300 MHz,
CD3OD): 8.31 (d, 1 H, J2,3 = 4 Hz, H-2’); 8.08 (d, 1 H,
J5,6 = 6 Hz, H-5’); 7.88 (s, 1 H, H-4” triazole); 7.73 (s,
1 H, H-8’); 7.37 (dd, 1 H, J6,5 = 6 Hz, J= 2 Hz, H-6’); 6.51
(d, 1 H, J3,2 = 4 Hz, H-3’); 4.53 (s, 1 H, H-12); 3.60 (s,
1 H, H-7); 3.89 (s, 2 H, H-3”); 3.49 (s, 3 H, H-25); 3.45
(m, 2 H, H-1”); 2.93 (m, 2 H, H-2”); 0.97 (d, 3 H,
J= 6 Hz, H-21); 0.76 (s, 3 H, H-18); 0.65 (s, 3 H, H-19);
13C NMR (75 MHz, CD3OD): 176.4 (C-24); 152,6 (C-4’);
152.0 (C-2’); 149.3 (C-9’); 146.3 (C-3” triazole); 136.3 (C-
7’); 127.3 (C-8’); 125.9 (C-6’); 124.3 (C-4” triazole); 123.3
(C-5’); 118.6 (C-10’); 99.5 (C-3’); 73.7 (C-12); 68.7 (C-7);
58.2 (C-3); 51.8 (C-13); 48.8 (C-25); 47.1 (C-2); 23.3 (C-
21); 17.4 (C-19); 12.8 (C-18); HRMS ESI [M+H]+: m/z:





5β-cholane-24-oate (13): Yellow oil; υmax (KBr): 3345
(NH), 2928 (CH); 1H NMR (300 MHz, CDCl3): 8.38 (d,
1 H, J2,3 = 4 Hz, H-2’); 7.87 (s, 1 H, H-8’); 7.74 (d, 1 H,
J5,6 = 6 Hz, H-5’); 7.52 (s, 1 H, H-5” triazole); 7.20 (dd,
1 H, J6,5 = 6 Hz, J= 2 Hz, H-6’); 6.27 (d, 1 H, J3,2 = 4 Hz,
H-3’); 4.53 (s, 2 H, H-4”); 3.87 (s, 1 H, H-7); 3.65 (s, 3 H,
H-25); 3.45 (m, 2 H, H-1”); 0.97 (d, 3 H, J= 6 Hz, H-21);
0.81 (s, 3 H, H-18); 0.68 (s, 3 H, H-19); 13C NMR
(75 MHz, CDCl3): 174.9 (C-24); 151.4 (C-4’); 150.2 (C-
2’); 144.6 (C-9’); 144.6 (C-4” triazole); 135.5 (C-7’); 126.8
(C-8’); 125.4 (C-6’); 123.0 (C-5” triazole); 122.9 (C-5’);
121.4 (C-10’), 114.0 (C-3’), 73.0 (C-12), 68.2 (C-7), 57.0
(C-3), 51.7 (C-13), 48.4 (C-25), 47.4 (C-2), 38.3 (C-14);
22.9 (C-21); 17.5 (C-19); 12.7 (C-18); HRMS ESI [M+H]+:





5β-cholane-24-oate (14).Yellow oil; υmax (KBr): 3347 (NH), 2931 (CH);
1H
NMR (300 MHz, CDCl3): 8.44 (d, 1 H, J2,3 = 2 Hz, H-2’);
7.88 (s, 1 H, H-8’); 7.77 (d, 1 H, J5,6 = 6 Hz, H-5’); 7.51
(s, 1 H, H-7” triazol); 7.23 (dd, 1 H, J6,5 = 6 Hz, J= 2 Hz,
H-6’); 6.32 (d, 1 H, J3,2 = 2 Hz, H-3’); 3.92 (s, 2 H, H-4”);
3.88 (s, 1 H, H-7); 3.66 (s, 3 H, H-25); 3.28 (m, 2 H, H-
1”); 0.99 (d, 3 H, J= 6 Hz, H-21); 0.82 (s, 3 H, H-18);
0.68 (s, 3 H, H-19); 13C NMR (75 MHz, CDCl3): 174.9
(C-24); 151.6 (C-4’); 150.5 (C-2’); 148.7 (C-9’); 145.3 (C-
6” triazole); 134.8 (C-7’); 127.8 (C-8’); 124.9 (C-6’); 122.3
(C-7” triazole); 121.2 (C-5’); 117.4 (C-10’); 98.8 (C-3’);
72.9.0 (C-12); 68.0 (C-7); 56.9 (C-3); 51.6 (C-13); 48.7
(C-25); 47.3 (C-2); 22.9 (C-21); 17.5 (C-19); 12.7 (C-18);
HRMS ESI [M+H]+: m/z: Calc for C41H60N6O4Cl
735.4365 [M+H]+, found 735.4362 [M+H]+.Biological evaluation
Anti-MTB activity
The anti-MTB activity of the compounds was deter-
mined by the Resazurin Microtiter Assay (REMA) [26].
Stock solutions of the test compounds were prepared in
dimethyl sulfoxide (DMSO) and diluted in Middlebrook
7 H9 broth (Difco), supplemented with oleic acid, albu-
min, dextrose and catalase (OADC enrichment—BBL/
Becton Dickinson, Sparks, MD, USA), to obtain final
drug concentration ranges from 0.15 to 250 μM. The
serial dilutions were realized in a Precision XS Micro-
plate Sample Processor (Biotek™). The isoniazid was dis-
solved in distilled water, as recommended by the
manufacturer (Difco laboratories, Detroit, MI, USA),
and used as a standard drug. MTB H37Rv ATCC 27294
was grown for 7 to 10 days in Middlebrook 7 H9 broth
supplemented with OADC, plus 0.05% Tween 80 to
avoid clumps. Cultures were centrifuged for 15 min at
3,150 g, washed twice, and resuspended in phosphate-
buffered saline and aliquots were frozen at −80°C. After
2 days, an aliquot was thawed to determine the viability
and the CFU after freezing. MTB H37Rv (ATCC 27294)
was thawed and added to the test compounds, yielding a
final testing volume of 200 μL with 2 × 104 CFU/mL.
Microplates with serial dilutions of each compound were
incubated for 7 days at 37°C, after resazurin was added
to test viability. Wells that turned from blue to pink,
with the development of fluorescence, indicated growth
of bacterial cells, while maintenance of the blue color
indicated bacterial inhibition [26]. The fluorescence was
read (530 nm excitation filter and 590 nm emission fil-
ter) in a SPECTRAfluor Plus (TecanW) microfluorimeter.
The MIC was defined as the lowest concentration result-
ing in 90% inhibition of growth of MTB. As a standard
test, the MIC of isoniazid was determined on each micro-
plate. The acceptable range of isoniazid MIC is from 0.11
to 0.44 μM [10,33]. Each test was set up in triplicate.
Figure 1 Reagents and conditions: (a) ethane-1,2-diamine, propane-1,3-diamine, or butane-1,4-diamine, 80°C for 1 h, 110°C for 4 h,
90%; (b) propargyl bromide, K2CO3, EtOH, 25°C, 48 h, 60%.
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Parasites and cell culture
Promastigote forms of L. major (MRHO/SU/59/P) were
maintained in Medium BHI supplemented with 10%
fetal bovine serum (FBS) at 24°C. FBS was purchased
from Cultilab (Campinas, São Paulo, Brazil) and brain
heart infusion (BHI) from Himédia (Mumbai, India).
Promastigote forms
The viability of parasites was determined by the colori-
metric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (purchased by Sigma Chemical Co., St.
Louis, MO, USA) or MTT method, based on tetrazolium
salt reduction by mitochondrial dehydrogenases [27].
Briefly, promastigotes of L. major from a logarithmic
phase culture were suspended to yield 2 million cells/
mL after Neubauer chamber counting. The screening
was performed in 96-well microtiter plates maintained
at 24°C. Controls with DMSO and without drugs were
performed. Absorbance was measured at 570 nm (Mul-
tiskan MS microplate reader, LabSystems Oy, Helsink,Figure 2 Reagents and conditions: (a) HCl/MeOH, 25°C, 24 h, 98%; (b)
70%.Finland). The results are expressed as the concentrations
inhibiting parasite growth by 50% (IC50) after a 3-day in-
cubation period. Amphotericin B (supplied by Cristália,
São Paulo, Brazil) was used as the reference standard.
For data analysis: IC50 values were carried out at 5% sig-
nificance level (p < 0.05, CI 95%), calculated using a non-
linear regression curve, by using GraFit Version 5
software (Erithacus Software Ltd., Horley, UK).
Amastigote forms
Concerning the amastigotes in vitro model, inflammatory
macrophages were obtained from BALB/c mice previously
inoculated with 3% thioglycollate medium (Sigma Chemical
Co.). Briefly, peritoneal macrophages were plated at 2×106
cells/mL on coverslips (13-mm diameter) previously
arranged in a 24-well plate in RPMI 1640 medium supple-
mented with 10% inactivated FBS, and allowed to adhere
for 24 h at 37°C in 5% CO2. Adherent macrophages were
infected with L. major (MRHO/SU/59/P) promastigotes in
the stationary growth phase using a ratio of 1:10 at 37°C for
3 h. Non-internalized promastigotes were eliminated andMsCl, Et3N, CH2Cl2, 0°C, 2 h, 80%; (c) NaN3, DMF, 120°C, 24 h,
Table 1 Effect of the compounds on promastigote forms
of L. major, murine peritoneal macrophages and M.
tuberculosis
Compounds Biological tests (μM)










Values represent the mean of triplicate samples.*AmB (amphotericin B) and
isoniazid were used as reference drug for antileishmanial and anti-MTB assays,
respectively. aIC50 values (concentrations inhibiting parasite growth by 50%).
bMIC: lowest concentration resulting in 90% inhibition of growth of MTB. cData
have been reported previously [24].
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at 37°C in 5% CO2 for 72 h. Slides were fixed and stained
with Giemsa for parasite counting (optical microscopy,
1000× magnification). Amphotericin B was used as a stand-
ard drug and the reduction of the number of amastigotes
was evaluated after only 24-h post-infection (0.1 μM=35%
and 1.0 μM=48% of reduction of intracellular amastigotes).
The data were analyzed using GraphPad Prism 5.0 (Graph-
Pad Software, San Diego, CA, USA), which considered the
mean of two assays performed in duplicate. One-way
ANOVA was applied to compare all the groups. Differences




The aminoquinoline/steroids conjugates 12, 13, and
14 were synthesized via 1,3-dipolar cycloaddition of al-
kyne 3, 5, or 7, respectively, with an azide group of
the bile acid 11. 4,7-dichloroquinoline 1 on treatment
with ethylenediamine, propanediamine, or butanedia-
mine at 80–110°C for 4 h furnished the intermediates
N-(2-aminoethyl)-7-chloroquinolin-4-amine (2), N-(3-
aminopropyl)-7-chloroquinolin-4-amine (4), and N-(4-
aminobutyl)-7-chloroquinolin-4-amine (6) in 90% yield
[25]. These intermediates 2, 4, or 6 on furtherFigure 3 Reagents and conditions: (a) CuSO4.5H2O, sodium ascorbatetreatment with propargyl bromide and K2CO3 in EtOH
at 25°C for 48 h yielded compounds 3, 5, and 7, re-
spectively, in 60% yield (see Figure 1) [28].
The C-3-azido steroid (bile acid) derivative 11 was
synthesized according to the literature procedures [29,30]
with small modifications (see Figure 2). Finally, the, DMSO/H2O (1:1), 25°C, 96 h, 60%.
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14 were synthesized in very high yield via 1,3-dipolar cyclo-
addition of alkyne 3, 5, or 7 with an azide group of the bile
acid 11, respectively, using CuSO45H2O, sodium ascor-
bate, DMSO/H2O (1:1) at 25°C for 96 h, in 60% yield (see
Figure 3). All the compounds were well characterized by
1H NMR, 13C NMR, and HRMS.Figure 4 Effect of alkyne intermediate structures (3, 5 and 7) and am
amastigotes. Peritoneal macrophages previously infected with L. major pr
compounds for 72 h. Results from two assays in duplicate are shown as pe
results were significant (***p< 0.0001).Biological evaluation
Previous study demonstrated that 4-amino-7-chloroqui-
noline derivatives (2–7) showed an interesting antileish-
manial and anti-MTB activities [24]. In continuation of
this study, novel steroid linked aminoquinolines were
synthesized in an anticipation to improve its biological
activity. Table 1 shows the biological results comparinginoquinoline/steroid conjugates (12, 13 and 14) on intracellular
omastigotes in the stationary growth phase were exposed to the
rcentage of growth inhibition in relation to untreated control. All
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corresponding aminoquinoline/steroid conjugate products
(12, 13, and 14).
Anti-MTB activity of the compounds increased in the
following order: alkyne intermediate structures (3, 5,
and 7) < aminoquinoline/steroid conjugates (12–14).
The aminoquinoline/steroid conjugates (12–14) showed
excellent results with MICs ranging from 8.8 to
17.3 μM. Within these conjugates, the compound 12
was the most active against MTB bacilli (8.8 μM) and
the presence of the shortest ethylenodiamine linker was
enough to demonstrate the improved activity. The mini-
mum inhibitory concentration (MIC) value found for
the compound 12 is comparable or better than the MIC
of some “second-line” drugs currently used in TB ther-
apy such as cycloserine (122.4–489.7 μM), kanamycin
(2.1–8.6 μM), tobramycin (8.6–17.1 μM), and clarithro-
mycin (10.7–21.4 μM) [31].
For antileishmanial test, the assay was performed in
both promastigote and amastigote forms of Leishmania
since both stages of parasite are used for drug screening
research [32-34]. Table 1 shows IC50 values of synthe-
sized compounds on promastigote forms of L. major.
Aminoquinoline/steroid conjugates (12–14) were more
active than the respective alkyne intermediate structures
(3, 5, and 7, respectively). Among them, the compound
12 was the most active in promastigotes of L. major,
inhibiting two times more the viability of the parasite
than the alkyne intermediate 3.
Although the promastigotes of the Leishmania genus are
used for screening of compounds, this assay must be con-
sidered as preliminary because: this stage of parasite is sig-
nificantly more susceptible to drug-induced effects than
amastigote, the amastigote are responsible for all clinical
manifestations in humans and the intracellular amastigote
model has been cited as the golden standard for in vitro
Leishmania drug discovery research [33,34]. L. major-
macrophage treated with the aminoquinoline/steroid
compounds (12–14) showed a significant inhibitory effect
against the intracellular amastigotes, as evidenced in
Figure 4. Addition of a steroid group to aminoquinoline
molecules again enhanced the biological activity of the
compounds. Results showed that the compounds 13 and
14 showed the best antiproliferative effects on intracellular
amastigotes, inhibiting between 64 and 80% of the parasite
burden. These assays were performed in concentrations
above those toxic for murine macrophages.
Antileishmanial and anti-MTB results confirm the im-
portance of steroid groups such cholic acid acting as car-
riers. The cholic acid-derived carriers can possibly
increase the solubility in physiological conditions and it
could lead to increased cell permeability due to the
amphiphilic character of the molecule and could func-
tion as an ionophore [22]. Further in vivo mouse modelstudies could better elucidate the role of bile acid deriva-
tives as carriers.
Conclusions
Regioselective synthesis of the novel aminoquinoline/
steroid conjugates was achieved in very high yield.
Addition of a steroid group to aminoquinoline molecules
enhanced the anti-MTB activity, having lower MICs
than some drugs commonly used to treat TB. For antil-
eishmanial assay, the aminoquinoline/steroid conjugates
demonstrated a significant activity against promastigote
and amastigote forms of L. major.
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